CONNECT 1906: PEP-CMV on HGG, DIPG, and MB - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults, Children
Study Details
Full Title
CONNECT 1906: Phase 2 trial of a novel peptide vaccine (PEP-CMV) targeting CMV antigen for newly diagnosed pediatric high-grade glioma (HGG) and diffuse intrinsic pontine glioma (DIPG) and recurrent medulloblastoma (MB).
Principal Investigator
Neuro-oncologist
Protocol Number
IRB:
PRO00109336
NCT:
NCT05096481
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment